Association of immune-related adverse events (irAEs) with clinical benefit in patients with metastatic urothelial carcinoma (mUC) treated with immune-checkpoint inhibitors (ICIs).

被引：0
|
作者：
Vitale, Nuzzo Pier
Pond, Gregory Russell
Abou Alaiwi, Sarah
Nassar, Amin
Flippot, Ronan
Choueiri, Toni K.
Harshman, Lauren Christine
Sonpavde, Guru
机构：
[1] Dana Farber Canc Inst, Boston, MA USA
[2] McMaster Univ, Dept Oncol, Hamilton, ON, Canada
[3] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[4] Hop Piti Salpetriere, Lab Avec Fdn, Paris, France
[5] Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA
[6] Harvard Med Sch, Boston, MA 02115 USA
[7] Stanford Univ, Sch Med, Stanford, CA 94305 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16038
引用
收藏
页数：1
相关论文
共 50 条
  • [31] IMMUNE-RELATED ADVERSE EVENTS (IRAES) MAY INDICATE A FAVORABLE PROGNOSIS IN METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS (ICI)
    Martini, Dylan
    Evans, Sean
    Goyal, Subir
    Liu, Yuan
    Olsen, T. Anders
    Magod, Benjamin
    Brown, Jacqueline
    Yantorni, Lauren
    Russler, Greta
    Caulfield, Sarah
    Goldman, Jamie
    Nazha, Bassel
    Harris, Wayne
    Master, Viraj
    Kucuk, Omer
    Carthon, Bradley
    Bilen, Mehmet
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A380 - A381
  • [32] Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors
    Sandigursky, Sabina
    Mor, Adam
    CURRENT RHEUMATOLOGY REPORTS, 2018, 20 (10)
  • [33] Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors
    Sabina Sandigursky
    Adam Mor
    Current Rheumatology Reports, 2018, 20
  • [34] ASSOCIATION BETWEEN IMMUNE-RELATED ADVERSE EVENTS AND SURVIVAL OF PATIENTS WITH METASTATIC UROTHELIAL CARCINOMA TREATED WITH PEMBROLIZUMAB
    Nakamura, Kazutaka
    Toshio, Takagi
    Nemoto, Yuki
    Ishiyama, Yudai
    Ishihara, Hiroki
    Tachibana, Hidekazu
    Fukuda, Hironori
    Shinmura, Hiroaki
    Hashimoto, Yasunobu
    Kondo, Tsunenori
    Yoshida, Kazuhiko
    Iizuka, Junpei
    Ishida, Hideki
    Tanabe, Kazunari
    JOURNAL OF UROLOGY, 2022, 207 (05): : E28 - E28
  • [35] Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors
    Cook, Sarah
    Samuel, Vanessa
    Meyers, Daniel E.
    Stukalin, Igor
    Litt, Ishjot
    Sangha, Randeep
    Morris, Don G.
    Heng, Daniel Y. C.
    Pabani, Aliyah
    Dean, Michelle
    Navani, Vishal
    JAMA NETWORK OPEN, 2024, 7 (01) : E2352302
  • [36] Correlation between immune-related adverse events (irAEs) and efficacy in patients with solid tumors treated with immune-checkpoints inhibitors (ICIs).
    Riudavets, Mariona
    Barba, Andres
    Maroto, Pablo
    Sullivan, Ivana Gabriela
    Anguera, Georgia
    Paez, David
    del Carpio, Luis
    Callejo, Ana
    Gonzalez Blanco, Cintia
    Garcia Planellas, Esther
    Castillo, Diego
    Facundo, Carme
    Genua, Idoia
    Martin Lorente, Cristina
    Virgili, Ana
    Sebio, Ana
    Gallego, Oscar
    Lopez-Pousa, Antonio
    Barnadas, Agust
    Majem, Margarita
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [37] Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)
    Daban, A.
    Gonnin, C.
    Phan, L.
    Saldmann, A.
    Granier, C.
    Lillo-Lelouet, A.
    Le Beller, C.
    Pouchot, J.
    Weiss, L.
    Tartour, E.
    Fabre, E.
    Medioni, J.
    Oudard, S.
    Vano, Y. A.
    Dragon-Durey, M. A.
    Simonaggio, A.
    ONCOIMMUNOLOGY, 2023, 12 (01):
  • [38] Autoantibodies as potential biomarkers of high grade immune-related adverse events (irAEs) in metastatic melanoma patients treated with check point inhibitors (ICIs)
    Gandhi, A.
    Taylor, J.
    Morici, M.
    Reid, A.
    Meniawy, T.
    Khattak, M. A.
    Millward, M.
    Gray, E. S.
    Zaenker, P.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S597 - S597
  • [39] Association of immune-related adverse (irAEs) with immunecheckpoint inhibitors (ICIs) efficacy in solid tumors
    Riudavets Melia, M.
    del Carpio, L. P.
    Gabriela Sullivan, I.
    Barba Joaquin, A.
    Maroto Rey, P.
    Anguera Palacios, G.
    Paez Lopez-Bravo, D.
    Callejo Perez, A.
    Gonzalez Blanco, C.
    Castillo Villegas, D.
    Facundo Molas, C.
    Garcia Planella, E.
    Genua Trullos, I.
    Lopez Pousa, A.
    Sebio Garcia, A.
    Martin Lorente, C.
    Virgili Manrique, A. C.
    Gallego Rubio, O.
    Barnadas Molins, A.
    Majem Tarruella, M.
    ANNALS OF ONCOLOGY, 2018, 29 : 427 - 427
  • [40] Molecular Mechanisms of Cutaneous Immune-Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitors
    Teng, Yi-Shan
    Yu, Sebastian
    CURRENT ONCOLOGY, 2023, 30 (07) : 6805 - 6819
12345